Group 1 - The commercial aerospace concept continues to strengthen, with companies like Jili Rigging and Hangxiao Steel Structure seeing three consecutive trading limit increases, while Tongyu Communication and Electronic Science Chip hit the daily limit, and other companies like Xinke Mobile and Star Map Measurement Control rose over 10% [1] - The Science and Technology Innovation 50 Index has expanded its gains to 1%, currently reported at 1491.58 points [2] - The A-share market opened with the Shanghai Composite Index up 0.35%, the Shenzhen Component Index up 0.47%, while the ChiNext Index opened down 0.13% [3] Group 2 - The AI application sector is active, with e-commerce and short drama gaming sectors leading in gains; the commercial aerospace index continues to develop, while energy metal concept stocks are gaining strength [4] - Individual stocks such as Tianpu Co., Guosheng Technology, and Jiamei Packaging have resumed trading, with Tianpu Co. opening at a daily limit down due to an investigation by the China Securities Regulatory Commission, while Guosheng Technology rose nearly 8% and Jiamei Packaging hit the daily limit [4] - Defu Technology opened down over 11% after terminating the acquisition of 100% equity in Luxembourg Copper Foil [6] Group 3 - The Hong Kong stock market opened with the Hang Seng Index up 0.55% and the Hang Seng Technology Index up 0.88%, with companies like WuXi Biologics, Meituan, Baidu Group, Zijin Mining, and Bilibili rising over 2% [6]

Group 1 - The commercial aerospace concept continues to strengthen, with companies like JuLi SuoJu and Hangxiao Steel Construction seeing three consecutive trading limits, while Tongyu Communication and Electronic Science Chip hit the daily limit, and companies like Xinke Mobile and Star Map Measurement Control rose over 10% [3][6] - The Science and Technology Innovation 50 Index has expanded its gains to 1%, currently reported at 1491.58 points [4] - The A-share market opened with the Shanghai Composite Index up 0.35%, the Shenzhen Component Index up 0.47%, while the ChiNext Index opened down 0.13% [5][6] Group 2 - AI application themes are active, with e-commerce and short drama gaming sectors leading in gains; the commercial aerospace index continues to develop, while energy metal concept stocks are gaining strength [6] - Individual stocks such as Tianpu Co., Guosheng Technology, and Jiamei Packaging have resumed trading, with Tianpu Co. opening at a limit down due to an investigation by the China Securities Regulatory Commission [6] - Defu Technology opened down over 11% after terminating the acquisition of 100% equity in a Luxembourg copper foil company [8] Group 3 - The Hong Kong stock market opened with the Hang Seng Index up 0.55% and the Hang Seng Technology Index up 0.88%, with companies like WuXi Biologics, Meituan, Baidu Group, and Zijin Mining rising over 2% [8][9] - The "first global large model stock" Zhihui rose nearly 15% [8]

Market Overview - The A-share market opened with the Shanghai Composite Index up by 0.35% and the Shenzhen Component Index up by 0.47%, while the ChiNext Index opened down by 0.13% [1][2] - The Science and Technology Innovation Board Index increased by 0.86%, reaching 1818.96 points [2] Sector Performance - AI application themes are active, with e-commerce and short drama gaming sectors showing significant gains [1][2] - The commercial aerospace index continues to strengthen, with companies like Jili Rigging and Hangxiao Steel Structure achieving three consecutive trading limit increases [1] - Energy metal concept stocks are also gaining traction, while CPO and photovoltaic concept stocks are weakening [2] Individual Stock Movements - Tianpu Co., Guosheng Technology, and Jiamei Packaging are notable stocks, with Tianpu Co. opening at a limit down due to an investigation by the China Securities Regulatory Commission [2] - Guosheng Technology rose nearly 8%, and Jiamei Packaging hit the trading limit [2] - Defu Technology opened down over 11% after terminating the acquisition of 100% equity in a Luxembourg copper foil company [3][4] Hong Kong Market - The Hang Seng Index opened up by 0.55%, with the Hang Seng Tech Index rising by 0.88% [5][6] - Notable gainers include WuXi Biologics, Meituan, Baidu Group, Zijin Mining, and Bilibili, all rising over 2% [5] - Zhipu AI, referred to as the "first global large model stock," surged nearly 15% [5] Economic Indicators - The central bank conducted a 861 billion yuan reverse repurchase operation with an interest rate of 1.4%, while 500 billion yuan of reverse repos matured on the same day [6] - The RMB to USD central parity rate was reported at 7.0108, an increase of 20 basis points from the previous day [6]

Market Overview - The A-share market is showing strong performance, with the Shanghai Composite Index surpassing 4100 points and trading volume exceeding 3 trillion [1] - The Hong Kong market is lagging, influenced by overseas events, particularly geopolitical tensions involving Iran and Mexico [1] - The U.S. Supreme Court's delay in ruling on tariffs is seen as a positive development for the market [1] Industry Insights - The commercial aerospace sector is highlighted as a strong investment theme, with China submitting applications for an additional 203,000 satellites, covering 14 satellite constellations [1] - The U.S. FCC has approved SpaceX's deployment of 7,500 second-generation satellites, indicating a competitive landscape in satellite technology [1] Company Developments - SanDisk has introduced a novel contract requiring full cash prepayment from clients to secure supply quotas for 1 to 3 years, benefiting the related supply chain [2] - New Sword Transmission, a key supplier for Tesla's humanoid robot, has initiated its IPO process, marking a significant milestone in the mass production of humanoid robots [2] Financial Highlights - WuXi Biologics reported a record high of 209 new projects signed in 2025, with a significant portion coming from the U.S. market [3] - The company has 945 ongoing projects, including 74 in Phase III clinical trials, which are expected to drive future revenue growth [3] - WuXi Biologics anticipates a 120%+ year-on-year revenue growth in 2025, with a total potential milestone payment of over $4 billion from collaborative projects [3] Technological Advancements - OpenAI has launched ChatGPT Health, integrating user medical records and health data to assist in understanding health reports and preparing for medical consultations [4] - The AI-assisted diagnostic services have been included in China's medical insurance framework, paving the way for more companies to apply for relevant certifications [5]

Core Viewpoint - The newly launched Hong Kong Stock Connect Medical ETF by Huabao (159137) is expected to perform actively due to the rising interest in the medical sector and favorable market conditions, coinciding with a strong performance in both the Hong Kong and A-share medical sectors at the beginning of 2026 [1][2]. Group 1: ETF Launch and Market Context - The Hong Kong Stock Connect Medical ETF Huabao (159137) was established on December 31, 2025, and began trading on January 12, 2026 [2]. - The underlying index, the "CSI Hong Kong Stock Connect Medical Theme Index," has seen a 14.25% increase from January 1 to January 9, 2026, and a total annual increase of 48.20% in 2025, indicating a strong recovery in the Hong Kong medical sector [2][4]. - The ETF's launch coincides with a rare "sixteen consecutive days of gains" in the Shanghai Composite Index, reflecting heightened investor enthusiasm [1]. Group 2: Investment Strategy and Composition - The ETF covers four major sectors within the Hong Kong medical field: CXO, medical business and services, medical devices, and biopharmaceuticals, with over 80% of its weight concentrated in leading companies in CXO, internet healthcare, and high-end medical devices [2][4]. - The top ten constituents of the index include major players such as WuXi Biologics (15.28% weight), JD Health (11.84%), and Alibaba Health (5.42%), collectively accounting for 63.89% of the index [4]. Group 3: Market Potential and Valuation - The Hong Kong medical sector is characterized by significant growth potential, driven by an aging population and increasing healthcare demands, with the CXO market expected to grow at a CAGR of 26.56% from 2020 to 2025 [4]. - The index's valuation remains relatively low, with a TTM P/E ratio of 29.43, which is below historical averages, suggesting a favorable entry point for investors [5].

根据香港交易所1月11日的文件显示，药明生物技术有限公司将在年度医疗健康大会上进行简报，该公 司稳步实现2025财年目标——收入和利润双双增长。该公司2026财年业务增长势头继续，受研究服务、 药物开发和生产业务所支撑。研究服务业务延续2024年强劲势头至2025年, CD3 TCE分子合作加速，平 台迎来战略节点。2025年合作项目的潜在里程碑付款总额高达40亿美元以上。 本文源自：金融界AI电报 ...

Core Viewpoint - The newly launched Hong Kong Stock Connect Medical ETF, Huabao (159137), is expected to perform actively due to the rising interest in the medical sector and favorable market conditions, coinciding with the recent recovery of the Hong Kong and A-share medical sectors at the beginning of 2026 [1][14]. Group 1: ETF Launch and Market Context - The Hong Kong Stock Connect Medical ETF Huabao (159137) was established on December 31, 2025, and began trading on January 12, 2026 [1][15]. - The Shanghai Composite Index has recently shown a rare "sixteen consecutive days of gains," surpassing the 4100-point mark, indicating high investor enthusiasm [1][14]. - The Hong Kong Stock Connect Medical Theme Index has increased by 14.25% from January 1 to January 9, 2026, and had an annual increase of 48.20% in 2025, reflecting a significant recovery in the medical sector [1][15]. Group 2: ETF Composition and Investment Focus - The ETF tracks the CSI Hong Kong Stock Connect Medical Theme Index, covering four major areas: CXO, medical business and services, medical devices, and biopharmaceuticals, with over 80% of its weight concentrated in leading companies in CXO, internet healthcare, and high-end medical devices [2][15]. - More than 85% of the ETF's components are "Hong Kong exclusive" stocks, including unique offerings like JD Health and Alibaba Health, which provide investors with significant opportunities in the Hong Kong medical sector [2][15]. Group 3: Market Potential and Valuation - The Hong Kong medical sector is characterized as a "golden track" with substantial market potential, driven by an aging population and increasing healthcare demand, supported by a growing GDP per capita [4][19]. - The CSI Hong Kong Stock Connect Medical Theme Index is currently at a historical low, with a drop of over 65% from its peak in 2021, and a price-to-earnings ratio (TTM) of 29.43, which is below 65% of its historical range [6][19]. - The index's configuration offers a compelling cost-performance ratio, making the ETF a noteworthy investment tool for investors [6][19].

Core Viewpoint - WuXi Biologics (02269.HK) is set to participate in the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2024, where it will present updates on its business operations and financial performance [1] Group 1: Business Performance - The company reported a strong business and financial performance, with 209 new projects expected in 2025, bringing the total to 945 projects, including 74 in Phase III clinical trials and 25 CMO (Contract Manufacturing Organization) projects [1] - The research platform continues to show robust momentum, with record upfront and total payments in 2025, and new research contracts with potential milestone payments exceeding $4 billion [1] Group 2: Market Opportunities - Two-thirds of the new projects are focused on bispecific antibodies, multispecific antibodies, and ADCs (Antibody-Drug Conjugates), which are expected to drive innovation and open exciting market opportunities for the company [1] - The company completed 28 PPQ (Process Performance Qualification) projects in 2025, with 34 PPQ projects confirmed as of the announcement date in 2024, indicating a continuous increase in project activity [1] Group 3: Future Outlook - The company expresses confidence in maintaining growth momentum into 2026 and remains optimistic about its future prospects [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 內幕消息 二零二六年度醫療健康大會簡報 本公告由WuXi Biologics (Cayman) Inc.藥明生物技術有限公司*（「本公司」）根據 香港聯合交易所有限公司證券上市規則（「上市規則」）第13.09條及香港法例第 571章《證券及期貨條例》第XIVA部項下內幕消息條文（定義見上市規則）而作出。 本公司將於二零二六年一月十四日（美國太平洋時間）出席第44屆年度摩根大 通醫療健康大會（「年度醫療健康大會」），會上將進行包含本公司業務營運的 若干資訊的簡報（「簡報」）。為確保本公司所有股東及潛在投資者能夠公平及 時地取得該等信息，本公司於本公告納入簡報全文。本公司股東及潛在投資者 務請注意，簡報可能包含前瞻性陳述，該等陳述就其性質而言存在風險及不確 定性，簡報中陳述的任何估計及未來建議均基於若干假設及估計以及管理層 僅根據當前可得資料作出的判斷。 – 1 – 誠如簡報中所披露，本集團業務及財務表現依 ...

Group 1 - The Hang Seng Index closed down 0.94%, with the technology sector experiencing the largest decline [1] - The Hang Seng Technology Index fell by 1.81%, with notable drops from BYD Co. Ltd. (-3.93%), Alibaba (-3.25%), and NetEase (-2.88%) [3] - The Hang Seng Bank Index also saw a decline of 1.1%, with Standard Chartered down 2.43% and China Construction Bank down 1.42% [3] Group 2 - The Hang Seng Healthcare Index rose by 2.47%, driven by significant gains from companies like CanSino Biologics (+7.31%) and 3SBio (+7.16%) [3] - Other healthcare stocks such as WuXi Biologics and Innovent Biologics also saw increases of 5.92% and 5.38% respectively [3] - More than ten healthcare stocks recorded gains exceeding 3% [3]